Business Context and Reporting Period
Company: Capricor Therapeutics, Inc. (CAPR)
Filing Type: Form 8-K (Current Report)
Date of Report: November 7, 2019
Reporting Period: Third Quarter ended September 30, 2019
Business Context: The filing serves to announce the Company's financial results for the quarter ended September 30, 2019, via a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific financial data. It references a press release (Exhibit 99.1) for details on revenue, profit, cash flow, margins, debt, and liquidity. Consequently, the filing text does not provide a clear value for any specific financial metric.
Material Changes
The filing text does not disclose specific material changes versus the prior comparable period. It only indicates that such information is contained within the attached press release.
Guidance, Outlook, and Risks
Outlook and Commentary: The filing references a press release titled "Capricor Therapeutics Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Update," implying that management commentary and corporate updates are included in the exhibit, but the text of this 8-K does not summarize them.
Risks and Contingencies: No specific risks or contingencies are detailed in the provided text.
Unusual Items: None identified in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q3 2019 revenue, net loss, and cash position figures.
- Verify the "Recent Corporate Update" mentioned in the press release title for operational milestones or pipeline developments.
- Confirm the Company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Check the Nasdaq Capital Market listing status for the Common Stock (Symbol: CAPR).